Pharmanutra SpA
MIL:PHN

Watchlist Manager
Pharmanutra SpA Logo
Pharmanutra SpA
MIL:PHN
Watchlist
Price: 53.8 EUR 0.19% Market Closed
Market Cap: 516.9m EUR
Have any thoughts about
Pharmanutra SpA?
Write Note

Pharmanutra SpA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharmanutra SpA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Pharmanutra SpA
MIL:PHN
Interest Income Expense
-€986k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intercos SpA
MIL:ICOS
Interest Income Expense
-€11.5m
CAGR 3-Years
-140%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Bioera SpA
MIL:BIE
Interest Income Expense
€775k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Enervit SpA
MIL:ENV
Interest Income Expense
€96.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharmanutra SpA
Glance View

Market Cap
516.9m EUR
Industry
Consumer products

Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

PHN Intrinsic Value
43.41 EUR
Overvaluation 19%
Intrinsic Value
Price

See Also

What is Pharmanutra SpA's Interest Income Expense?
Interest Income Expense
-986k EUR

Based on the financial report for Jun 30, 2024, Pharmanutra SpA's Interest Income Expense amounts to -986k EUR.

Back to Top